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R Vandamme 1 . 1Laboratorium voor Microbiologie, Universiteit Gent, Gent, 
Belgium; 2Department of Biological Sciences, Warwick Universily, Coventry; 
3 Cardiff'School of  Biosciences, Cardiff" University, Cardiff, UK 
The Burkholderia cepacia complex (Bcc) is an important group of organisms, 
containing species of ecological, biotechnological nd pathogenic interest. Their 
taxonomy and identification are complex and are being studied through classi- 
cal polyphasic taxonomic approaches and through multi-locus sequence typing 
(MLST). We recently demonstrated that Burkholderia ubonensis, a species thus 
far not encountered in CF specimens, represents a tenth genomovar within the 
complex. 
Among thousands of Bcc isolates, we delineated five clusters of strains, both by 
polyphasic taxonomy as well as through MLST analysis that cannot be classified 
into one of the ten established Bcc species, and thus represent five novel Bcc 
species. Two of these novel species have been isolated from CF specimens only; 
the others have been isolated from infections in CF and non-CF patients, and 
from environmental sources. Although all five novel species clearly represent rarely 
encountered bacteria, we have designed novel recA gene based PCR tests for their 
specific identification. 
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~4]  The impact of MRSA colonization rates in one adult CF centre 
M.J. Ledson, K. Bashir, Y. Arunan, M.J. Walshaw. Regional Adult CF Unit, The 
Cardiothoracic Centre, Liverpool, UK 
Introduction: Although some CF units have reported an increasing prevalence 
of MRSA, there is controversy regarding the importance of this organism in CE 
Although we do not have a routine MRSA eradication policy, our heart/lung hospital 
has stringent cross infection precautions to prevent MRSA spread, and we had not 
noticed MRSA as a problem in our CF patients. To look at this further, we have 
compared the MRSA colonization rates in our unit over time. 
Methods: We undertook a cross-sectional microbiological survey of staphylococcal 
organisms from all CF patients attending our regional adult unit in 1999 and again 
in 2004. We looked at the prevalence of MRSA and whether it was intermittent 
and whether patients were taking prophylactic antistaphylococcal therapy. 
Results: In 1999, 47 of 121 patients (39%) had at least one culture ofS. aureus, of 
whom 43 (92%) were taking antistaphylococcal prophylaxis. Eight of these (6.6% 
of the whole clinic) grew MRSA, 7 of which were intermittent (<3 cultures in a 
6 month period). In 2004, 51 of 177 patients (29%) had at least one culture of 
S. aureus, and 39 of these (77%) were taking anti-staphylococcal prophylaxis. Six 
of these (3.4% of the whole clinic) grew MRSA, of which 4 were intermittent. Of 
those patients with positive MRSA cultures in 1999, one had died and one had left 
the area, but the remaining 6 patients had no positive cultures in 2004. 
Conclusions: Thus, we have shown that in our unit, MRSA colonization of 
CF patients is very limited, and the few patients who acquire it do not usually 
become colonized but clear it over time. These data suggest that strategies aimed 
at preventing cross infection may be more important that eradication policies in 
tackling MRSA in CF units. 
~3]  Timing of bacterial colonization in Cystic Fibrosis with emphasis 
on Staphylococcus aureus 
H.A.RH.M. Souza, K.S. Nogueira, A.R Matos, C.A. Riedi, R.R Vieira, L.M. Dalla- 
Costa, N.A. Rosfirio. Federal University of Parana, Curitiba, Brazil 
Background: pulmonary infection by P aeruginosa is the major cause of death in 
patients with cystic fibrosis (CF). It is suggested that S. aureus airway colonization 
in infants with CF provides a favorable nvironment toP aeruginosa installation. 
Aim: to verify through serial bacterial cultures the timing of bacterial colonization 
in the first years of life. 
Methods and Subjects: this was a prospective valuation of 25 CF patients 
diagnosed after positive neonatal screening by IRT. At routine periodical visits 
oropharyngeal swabs were obtained for microbiological nalysis. Two hundred and 
thirty three oropharyngeal cultures were collected (average of 9 per patient), within a 
median interval of 53 days, for one year. S. aureus, P aeruginosa, Haemophilus spp., 
S. pneumoniae and B. cepacia colonies were identified by standard methods and 
tested for antimicrobial susceptibility by agar dilution method. S. aureus isolates 
were molecularly typed by pulsed field gel electrophoresis (PFGE). 
Results: S. aureus was shown to be the first bacterium to colonize the pa- 
tients' oropharynx (after 214 days, on average), and more frequently (42%) than 
Haemophilus pp. (19%) and P aeruginosa (16%). The isolates were susceptible 
to ciprofloxacin (74% of isolates), erythromycin (69%), gentamicin (64%), sul- 
famethoxazole/trimethoprim (76%) and vancomycin (100%). Methycillin-resistant 
S. aureus isolates (25%) had PFGE profiles identical to the Brazilian clone. 
P aeruginosa isolates were non-mucoid and multisusceptible. 
Conclusion: S. aureus and Haemophilus pp. colonized the CF patients airways 
earlier than other common agents in CF, followed by non-mucoid strains of 
P aeruginosa. 
• ] A  UK national audit of MRSA prevalence and eradication 
strategies in Cystic Fibrosis 
J.C. Dewar. Adult CF Unit, Nottingham City Hospital, Nottingham 
Introduction: The prevalence of MRSA in CF in the UK is unclear, but reported 
at 2 3% [1,2]. Only one study has shown correlation with clinical deterioration [1], 
hence it is unclear as to whether clinicians hould routinely attempt to eradicate on 
acquisition. Furthermore, only two small case-series have reported the effectiveness 
of eradication [3,4]. Given the paucity of literature on the prevalence and eradication 
of MRSA, we conducted a national audit. 
Aims: to determine: 
• Prevalence of MRSA in sputum. 
• How many centres routinely eradicate on acquisition. 
• Eradication protocols. 
• Reasons for not attempting eradication. 
• Interest in an eradication trial. 
Methods: An anonymous postal questionnaire auditing prevalence of MRSA and 
eradication strategies was sent to all 60 UK adult and paediatric CF centres in 2005. 
Results: Response rate 76% (43 centres), information obtained for 4537 patients: 
Prevalence 
Range 
How many centtes routinely et-adicate? 
How many centtes have a standard Protocol? 
Eradication protocols 
Reasons for not et-adicating 
Interest in a National Trial 
259/4537 (5.7%) 
2 20% 
81.4% (n 35) 
55.8% (n 24) 
No consistent approach. Rirampicin and Fusidic acid colnlnonest. 
No evidence of MRSA causing a deteriot-ation 20.9% (n 9); or that 
et-adication works 18.6% (n 8); MRSA disapFearing without 
tteatlnent 13.93% (n 6) 
62.8% (n 27) 
Summary: 
• UK prevalence 5.7% 
• BUT range 2 20%, indicating some centres have a much higher prevalence than 
previously reported [1,2]. 
• Wide range of eradication protocols in UK CF centres. 
• Whilst most centres eradicate, attitudes to eradication are ambivalent. 
• Majority interest in National trial for eradication. 
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